title: Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women.
abstract: BACKGROUND
  Worldwide, cervical cancer is the second most common cancer in women. High-risk human papillomavirus (HPV) play a crucial role in the etiology of cervical cancer and the most prevalent genotype is HPV16. HPV 16 intratypic variants have been reported to differ in their prevalence, biological and biochemical properties. The present study was designed to analyze and identify HPV type 16 E6 variants among patients with cervical cancer in Morocco.
  
  
  METHODS
  A total of 103 HPV16 positive samples were isolated from 129 cervical cancer cases, and variant status was subsequently determined by DNA sequencing of the E6 gene.
  
  
  RESULTS
  Isolates from patients were grouped into the European (E), African (Af) and North-American (NA1) phylogenetic clusters with a high prevalence of E lineage (58.3%). The Af and NA1 variants were detected in 31.1% and 11.6% of the HPV16 positive specimens, respectively, whereas, only 3% of cases were prototype E350T. No European-Asian (EA), Asian (As) or Asian-American (AA) variants were observed in our HPV16-positive specimens. At the amino acid level, the most prevalent non-synonymous variants were L83V (T350G), H78Y (C335T), E113D (A442C), Q14D (C143G/G145T) and R10I (G132T), and were observed respectively in 65%, 41.8%, 38.8%, 30.1% and 23.3% of total samples.Moreover, HPV16 European variants were mostly identified in younger women at early clinical diagnosis stages. Whereas, HPV16 Af variants were most likely associated with cervical cancer development in older women with pronounced aggressiveness.
  
  
  CONCLUSIONS
  This study suggests a predominance of E lineage strains among Moroccan HPV 16 isolates and raises the possibility that HPV16 variants have a preferential role in progression to malignancy and could be associated with the more aggressive nature of cervical cancer.
authors: Unité de Biologie et Recherche Médicale, Centre National de l'Energie, des Sciences et des Techniques Nucléaires, (CNESTEN), BP 1382 RP, 10001 Rabat, Morocco.
authors: Zineb
authors: Z
authors: Qmichou
authors: Meriem
authors: M
authors: Khyatti
authors: Mohamed
authors: M
authors: Berraho
authors: My Mustapha
authors: MM
authors: Ennaji
authors: Laila
authors: L
authors: Benbacer
authors: Chakib
authors: C
authors: Nejjari
authors: Noureddine
authors: N
authors: Benjaafar
authors: Abdellatif
authors: A
authors: Benider
authors: Mohammed
authors: M
authors: Attaleb
authors: Mohammed
authors: M
authors: El Mzibri
mesh_terms: D000328:Adult; D000367:Age Factors; D005260:Female; D005838:Genotype; D052162:Human papillomavirus 16 / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D009154:Mutation; D009367:Neoplasm Staging; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D012097:Repressor Proteins / Q000235:genetics*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000821:virology*
chemical_list: C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D012097:Repressor Proteins
references: Oncogene. 1996 Oct 3;13(7):1545-8
references: 8875993
references: Arch Med Res. 2009 Aug;40(6):428-34
references: 19853182
references: Int J Gynecol Cancer. 2006 Mar-Apr;16(2):736-42
references: 16681754
references: Virus Res. 2008 Jan;131(1):106-10
references: 17869365
references: BMC Clin Pathol. 2009 May 22;9:3
references: 19463165
references: J Gen Virol. 2006 May;87(Pt 5):1181-1188
references: 16603519
references: J Med Virol. 2004 Sep;74(1):117-26
references: 15258977
references: Nat Med. 1995 May;1(5):464-70
references: 7585096
references: PLoS One. 2012;7(5):e36577
references: 22574185
references: J Med Virol. 2007 Dec;79(12):1889-97
references: 17935194
references: J Virol. 1997 Mar;71(3):2463-72
references: 9032384
references: Future Oncol. 2009 Apr;5(3):359-70
references: 19374542
references: J Med Virol. 2003 Apr;69(4):546-52
references: 12601763
references: J Gen Virol. 2000 Feb;81(Pt 2):317-25
references: 10644829
references: Br J Cancer. 2002 Jan 21;86(2):269-73
references: 11870518
references: J Natl Cancer Inst. 2006 Aug 2;98(15):1045-52
references: 16882941
references: J Med Virol. 2009 Apr;81(4):678-84
references: 19235879
references: Int J Infect Dis. 2007 Jan;11(1):76-81
references: 16859947
references: Cancer Res. 2003 Nov 1;63(21):7215-20
references: 14612516
references: Gynecol Oncol. 2010 May;117(2):297-301
references: 20207397
references: Lancet Oncol. 2010 Nov;11(11):1048-56
references: 20952254
references: Clin Microbiol Infect. 2003 Feb;9(2):144-8
references: 12588336
references: Virology. 2004 Jun 20;324(1):17-27
references: 15183049
references: Int J Cancer. 1999 Sep 24;83(1):34-7
references: 10449604
references: Biochem Pharmacol. 2010 Dec 15;80(12):1930-5
references: 20643111
references: Hum Immunol. 2003 May;64(5):538-42
references: 12691704
references: J Virol. 2003 Jan;77(2):1551-63
references: 12502868
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Int J Cancer. 2011 Feb 15;128(4):927-35
references: 20473886
references: N Engl J Med. 2003 Feb 6;348(6):518-27
references: 12571259
references: Virology. 1985 Aug;145(1):181-5
references: 2990099
references: J Virol. 1992 Apr;66(4):2057-66
references: 1312620
references: J Virol. 2012 Jun;86(12):6855-61
references: 22491459
references: J Virol. 2005 Jun;79(11):7014-23
references: 15890941
references: J Virol. 1995 Dec;69(12):7743-53
references: 7494284
references: J Clin Microbiol. 2008 Mar;46(3):1060-6
references: 18199779
references: Gynecol Oncol. 2006 Aug;102(2):230-5
references: 16427686
references: Med Oncol. 2010 Sep;27(3):861-6
references: 19771536
references: Eur J Immunol. 1994 Dec;24(12):3175-9
references: 7805746
references: Infect Agent Cancer. 2007 Jun 05;2:11
references: 17550589
references: Int J Cancer. 2009 Dec 1;125(11):2609-13
references: 19569178
references: Int J Cancer. 2007 Aug 1;121(3):621-32
references: 17405118
references: J Med Virol. 2011 Apr;83(4):651-7
references: 21328380
references: J Natl Cancer Inst. 2001 Sep 5;93(17):1325-30
references: 11535707
references: Br J Cancer. 2003 Jul 7;89(1):101-5
references: 12838308
references: J Virol. 2004 Jun;78(11):5934-45
references: 15140991
references: Cancer Res. 2010 Apr 15;70(8):3159-69
references: 20354192
references: J Gen Virol. 2000 Dec;81(Pt 12):2959-2968
references: 11086127
references: Nat Rev Cancer. 2002 May;2(5):342-50
references: 12044010
references: Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):4-10
references: 17220325
references: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):820-2
references: 16614130
references: Int J Infect Dis. 2009 Mar;13(2):212-9
references: 18838282
references: Virology. 2009 Jan 5;383(1):69-77
references: 18986660
references: Virology. 2011 Feb 5;410(1):201-15
references: 21130481
references: Gynecol Oncol. 2011 Apr;121(1):32-42
references: 21211829
references: J Natl Cancer Inst. 2001 Feb 21;93(4):315-8
references: 11181779
references: Lancet. 1998 Oct 31;352(9138):1441-2
references: 9807995